雄激素难治性前列腺癌的化疗现状
摘要
激素难治性前列腺癌（HRPC）的治疗是一个极具挑战性的课题。近年来HRPC的化疗效果正逐渐得到提高。本文就HRPC的化疗进展作一综述。
出处
《国际泌尿系统杂志》
2009年第6期756-759,755,共5页
International Journal of Urology and Nephrology
参考文献22
-
1Aus G, Abbou CC, Bolla M, et al. European Association of Urology: EAU guidelines on prostate cancer. Eur Urol, 2005, 48 (4) : 546 - 551.
-
2Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estraustine compared with mitoxantrone and prednisone for advanced refractory prostatecancer. N Engl J Med, 2004, 351 (15) :1513 - 1520.
-
3Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitxantrone plus prednisone for advanced prostate cancer. N Engl J Med, 2004, 351(15):1502-1512.
-
4DiLorenzo G, Pizza C, Autorino R, et al. Weekly docetaxel and vinorelbine( VIN- DOX) as first line treatment in patients with hormone refractory prostate cancer. Eur Urol, 2004, 46 (6) :712 - 716.
-
5Goodin S, Rao KV, Kane M, et al. A phase II trial of docetaxel and vinorelbine in patients with hormone - refractory prostate cancer. Cancer Chemother Pharmacol, 2005, 56 ( 2 ) : 199 - 204.
-
6Knatoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone - refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol, 1999, 17(8):2506-2513.
-
7Berry W, Dakhil S, Modiano M. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol, 2002, 168 (6) :2439 -2443.
-
8Hudes G, Einhom L, Ross E, et al. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone - refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase Ⅲ trial. J Clin Oncol, 1999, 17(10):3160-3166.
-
9Bracarda S, Tonato M, Rosi P, et al. Oral estramustine and cyclophosphamide in patienets with metastatic hormone refractory prostate carcinoma: A phase II study. Cancer, 2000, 88(6) :1438 -1444.
-
10Steinberg CN, Whelan P, Hetherington J, et al. Phase Ⅲ trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone - refractory prostate cancer. Oncology, 2005,68(1):2 -9.
-
1难治性前列腺癌可试试免疫治疗[J].医药前沿,2015,5(13):4-4.
-
2吴静,石志豪(综述),方克伟(审校).miRNA与肿瘤及前列腺癌关系的研究进展[J].国际泌尿系统杂志,2011,31(3):376-379.
-
3张姣,王海涛,杨庆,杜君,贾炜莹,张鹏宇.化疗前血清乳酸脱氢酶对去势难治性前列腺癌预后预测价值[J].中华肿瘤防治杂志,2015,22(14):1143-1146. 被引量：4
-
4王海涛,孟斌.去势难治性前列腺癌分子预后标志物研究进展[J].中国肿瘤临床,2014,41(15):1003-1006.
-
5刘峰,刘辉,王伟峰,郝继东,万建省.奥曲肽对多烯紫杉醇抑制激素难治性前列腺癌PC-3细胞的增效作用[J].蚌埠医学院学报,2013,38(12):1611-1613.
-
6全球医药快讯[J].世界临床药物,2013,34(6).
-
7周炫辰,王慕文.阿比特龙可延长转移性前列腺癌患者生存期[J].泌尿外科杂志（电子版）,2011(4):60-61. 被引量：2
-
8张姣,王海涛,杨庆,杜君,贾炜莹,张鹏宇.化疗前中性粒细胞与淋巴细胞比值对接受多西他赛化疗的去势难治性前列腺癌患者预后的影响[J].肿瘤,2015,35(3):333-339. 被引量：12
-
9范欣荣,李汉忠,石冰冰,纪志刚,夏溟,肖河,严维刚,周毅.多西他赛联合泼尼松治疗激素难治性前列腺癌的近期疗效观察[J].中华医学杂志,2007,87(24):1666-1668. 被引量：5
-
10醋酸阿比特龙对难治性前列腺癌有效[J].中华医学信息导报,2010,25(8):14-14.
